Trials / Completed
CompletedNCT00676533
Cipro® XR in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
Cipro® XR Excellence in Therapeutic Response and Activity (eXtRa) - Assessing Symptom Relief in Urinary Tract Infections
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 276 (actual)
- Sponsor
- Bayer · Industry
- Sex
- Female
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this clinical trial was to determine the time to improvement of the signs and symptoms (eg, dysuria, frequency, urgency, gross hematuria, suprapubic pain, hesitancy, low back pain) of acute, uncomplicated, symptomatic, lower UTIs in women treated with Cipro XR 500 mg once daily for 3 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Cipro XR (Ciprofloxacin, BAYQ3939) | 3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days. |
Timeline
- Start date
- 2003-06-01
- Completion
- 2004-01-01
- First posted
- 2008-05-13
- Last updated
- 2013-10-14
Locations
40 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00676533. Inclusion in this directory is not an endorsement.